Table 2.
comparison of our cohort to the DREAMM-2 cohort.
| Variable | Our cohort (N = 36) | DREAMM- 2 cohort 2.5 mg/kg (N = 97) |
|---|---|---|
| Median number of prior lines | 8 | 7 |
| The median time from diagnosis to first belantamab dose (years) | 7 | 5.5 |
| Median age at belantamab administration (years) | 67 | 65 |
| Extramedullary disease (%) | 14 | 23 |
| GFR < 30 (%) | 8 | 2 |
| Elderly | 13 (36%) over 70 | 13 (13%) over 75 |
| HR cytogenetics, n (%) | 14 (41%) | 41 (42%) |
| Prior CAR-T therapy, n (%) | 7 (19%) | 0 |
| Median PFS (month) | 2 | 2.8 |
| Median OS (months) | 6.5 | 13.8 |
| ORR (%) | 33 | 32 |
| CR/sCR | 6 | 7 |
| VGPR | 8 | 11 |
| PR | 19 | 13 |
| Keratopathy | 43% (G1 = 6 pt, G2 = 7 pt, G3 = 3 pt, G4 or 5 = 0) | 67% (G1–2 = 41 pt, G3 = 26 pt, G4 or 5 = 0) |
| IRR | 2 (5%) | 20 (21%) |
CR complete response, VGPR very good partial response, PR partial response, IRR infusion related reaction, GFR glomerular filtration rate, HR high risk.